← Back to Search

Norepinephrine Reuptake Inhibitor

TAK-503 for ADHD

Phase 4
Recruiting
Research Sponsored by Shire
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participant is a male or female aged 6 to 17 years inclusive at the time of consent/assent.
Participant has supine and standing blood pressure (BP) measurements less than the 95th percentile for age, sex, and height at both screening (Visit 1A) and baseline (Visit 2A).
Timeline
Screening 3 weeks
Treatment Varies
Follow Up part a: baseline, week 10, week 18, week 23, week 36, week 49, week 50, week 51 and week 52 part b: baseline, week 10, week 23, week 36, week 49, week 50, week 51 and week 52
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
Drug Has Already Been Approved
Pivotal Trial

Study Summary

This trial is studying a new medication for children and teenagers with ADHD who haven't responded well to other stimulant medications.

Who is the study for?
This trial is for children and teenagers aged 6 to 17 with ADHD who haven't responded well to stimulant therapy. They must have an intellectual function appropriate for their age, a certain score on the ADHD rating scale, and normal blood pressure. Those with heart issues, allergies to study drugs, or other significant health problems are excluded.Check my eligibility
What is being tested?
The trial tests TAK-503 against atomoxetine and placebo in kids and teens with ADHD over two parts. In Part A, participants randomly receive one of the three treatments; those on placebo then get TAK-503 in Part B while others continue on TAK-503.See study design
What are the potential side effects?
Possible side effects include sleepiness, headache, stomach pain, nausea, dizziness, mood swings and potentially low blood pressure. The exact side effects will vary between individuals based on their reaction to the medication.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 6 and 17 years old.
Select...
My blood pressure is below the high range for my age, sex, and height.
Select...
I have been diagnosed with ADHD by a psychiatrist.
Select...
My blood pressure, both lying down and standing, is within normal range for my age, sex, and height.
Select...
My intellectual functioning is appropriate for my age, as confirmed by a doctor.
Select...
I have been diagnosed with ADHD by a psychiatrist using the K-SADS-PL.
Select...
Stimulant medications were not suitable or effective for me, as confirmed by my doctor.
Select...
My blood pressure, both lying down and standing, is within normal range for my age, sex, and height.
Select...
My blood pressure, both lying down and standing, is below the high range for my age, sex, and height.
Select...
I have been diagnosed with ADHD by a psychiatrist.
Select...
I can swallow pills and capsules without any issues.
Select...
My parent or legal guardian and I agree to follow all study requirements.
Select...
I am a woman able to have children, not pregnant or breastfeeding, and agree to follow birth control rules.
Select...
My blood pressure is below the high range for my age, sex, and height.
Select...
I am between 6 and 17 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~part a: baseline, week 10, week 18, week 23, week 36, week 49, week 50, week 51 and week 52 part b: baseline, week 10, week 23, week 36, week 49, week 50, week 51 and week 52
This trial's timeline: 3 weeks for screening, Varies for treatment, and part a: baseline, week 10, week 18, week 23, week 36, week 49, week 50, week 51 and week 52 part b: baseline, week 10, week 23, week 36, week 49, week 50, week 51 and week 52 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Neuropsychological Tests
Change From Baseline in the Reaction Time (RTI) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) at Week 49
Change from Baseline in the Reaction Time (RTI) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) at Week 18
Secondary outcome measures
ADHD Rating Scale-5 (ADHD-RS-5) Total Score and Subscales
Brief Psychiatric Rating Scale for Children (BPRS-C)
Change From Baseline in the Delayed Matching to Sample (DMS) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) in Both Part A and Part B at Specified Time Points
+12 more

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Part B: Guanfacine hydrochloride (TAK-503)Experimental Treatment1 Intervention
Participants from Part A roll over into Part B, where participants received placebo in Part A will roll over after first 18 weeks and participants received TAK-503 or atomoxetine will roll over after 52 weeks of Part A. During Part B all the participants will receive TAK-503 at an initial dose of 1 mg, and up titrated with weekly incremental dose of 1 mg until an optimal dose is reached. Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive 5 to 7 mg TAK-503 oral tablet QD for 52 weeks of Part B.
Group II: Part A: Guanfacine hydrochloride (TAK-503)Experimental Treatment1 Intervention
Participants randomized to TAK-503 will receive initial dose of 1 milligram (mg), and up titrated with weekly incremental dose of 1 mg until an optimal dose is reached. Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive 5 to 7 mg TAK-503 oral tablet once daily (QD) for 52 weeks.
Group III: Part A: Atomoxetine hydrochlorideActive Control1 Intervention
Participants who weigh less than (<) 70 kilograms (kg) at baseline will receive active Atomoxetine hydrochloride capsule orally at an initial dose of 0.5 milligram per kilogram (mg/kg) which may be increased to the target dose of 1.2 mg/kg oral capsule QD during the treatment of 52 weeks. Permitted doses of Atomoxetine hydrochloride capsule will be 10, 18, 25, 40, 60, and 80 mg QD. Participants who weigh >= 70 kg at baseline will receive Atomoxetine hydrochloride at an initial dose of 40 mg oral capsule QD which may be increased to 80 mg and then to 100 mg for 52 weeks. The total dose for participants who weigh >= 70 kg at baseline will not exceed 100 mg.
Group IV: Part A: PlaceboPlacebo Group1 Intervention
Participants aged 6 to 12 years will receive a dose of 1 to 4 mg tablet of placebo matched to TAK-503 and aged 13 to 17 years will receive 5 to 7 mg tablets of placebo matched to TAK-503 orally QD for first 18 weeks. Participants who weigh < 70 kg at baseline will receive placebo matched to Atomoxetine hydrochloride oral capsule at an initial dose of 0.5 mg/kg which may be increased to the target dose of 1.2 mg/kg QD oral capsule during the treatment of first 18 weeks. Permitted doses of placebo matched to Atomoxetine hydrochloride will be 10, 18, 25, 40, 60, and 80 mg QD and participants who weigh >= 70 kg will receive placebo matched to Atomoxetine hydrochloride at an initial dose of 40 mg QD capsule orally which may be increased to 80 mg and then to 100 mg.

Find a Location

Who is running the clinical trial?

Takeda Development Center Americas, Inc.Industry Sponsor
56 Previous Clinical Trials
11,924 Total Patients Enrolled
ShireLead Sponsor
456 Previous Clinical Trials
97,263 Total Patients Enrolled
72 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
15,953 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)
Study DirectorStudy DirectorTakeda Development Center Americas
1,198 Previous Clinical Trials
489,698 Total Patients Enrolled
45 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
16,935 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)

Media Library

Atomoxetine hydrochloride (Norepinephrine Reuptake Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04085172 — Phase 4
Attention Deficit Hyperactivity Disorder (ADHD) Research Study Groups: Part A: Placebo, Part B: Guanfacine hydrochloride (TAK-503), Part A: Guanfacine hydrochloride (TAK-503), Part A: Atomoxetine hydrochloride
Attention Deficit Hyperactivity Disorder (ADHD) Clinical Trial 2023: Atomoxetine hydrochloride Highlights & Side Effects. Trial Name: NCT04085172 — Phase 4
Atomoxetine hydrochloride (Norepinephrine Reuptake Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04085172 — Phase 4
Attention Deficit Hyperactivity Disorder (ADHD) Patient Testimony for trial: Trial Name: NCT04085172 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the main goal of this experiment?

"This Baseline-Week 10 study seeks to evaluate the impact of TAK-503 on adolescents and children diagnosed with ADHD, by measuring Change From Baseline in the Reaction Time (RTI) Task at Week 49. Secondary objectives include tracking changes from baseline for Stop Signal Task (SST) and Rapid Visual Information Processing (RVP), as well as Brief Psychiatric Rating Scale for Children (BPRS-C). The SST task is used to measure response inhibition; participants must respond to an arrow stimulus while ignoring any accompanying audio tones. Simultaneously, RVP evaluates sustained attention over time, testing a participant's ability to detect"

Answered by AI

Who is qualified to participate in this investigation?

"This medical trial is recruiting two-hundred and eighty-eight patients, between the ages of six to seventeen years old, with an ADHD diagnosis. To qualify for this experiment, applicants must have a score higher than 28 on the Attention Deficit Hyperactivity Disorder Rating Scale 5 (ADHD-RS-5), as well as presenting a Clinical Global Impression Severity Score of four or greater at baseline. Furthermore, their blood pressure should be within normal ranges for age, sex and height measurements taken supine and standing both during screening visits and baselines tests. Lastly, participants need to demonstrate intellectual functioning appropriate for their age group when judged"

Answered by AI

What is the uppermost participant number associated with this research endeavor?

"This clinical trial, administered by Takeda Development Center Americas Inc. alongside Clinical Neuroscience Solutions in Memphis and Clinical Research Partners LLC from Petersburg requires 288 entrants to meet their criteria for inclusion."

Answered by AI

Does this clinical trial include older participants in their fifth decade or above?

"The protocol of this trial dictates that the minimum age for participation is 6 and the maximum age to be considered eligible is 17."

Answered by AI

What therapeutic applications has Guanfacine hydrochloride (TAK-503) been proven to be effective for?

"Guanfacine hydrochloride (TAK-503) is a medically useful compound, often prescribed to treat migraine. It can also prove beneficial in managing attention deficit hyperactivity disorder, hypertensive diseases and prophylactically preventing further migraine headaches."

Answered by AI

Are there any vacancies in this clinical trial for prospective participants?

"Affirmative. Clinicaltrials.gov provides evidence that this clinical trial, which was initially advertised on September 18th 2019, is still actively recruiting participants. There are 288 subjects needed from 23 different medical sites."

Answered by AI

Are there any precedents of research into Guanfacine hydrochloride (TAK-503)?

"At the moment, 20 clinical trials are testing the efficacy of Guanfacine hydrochloride (TAK-503), 4 of which have reached Phase 3. Locations running these studies range from Almere to California with 94 total sites offering access to TAK-503 treatment research."

Answered by AI

Does TAK-503 pose any risks to patients when administered?

"Our team at Power has rated the safety of Guanfacine hydrochloride (TAK-503) as 3 based on its Phase 4 status which indicates that it is approved."

Answered by AI

Are there multiple centers in the US that are currently conducting this investigation?

"23 medical sites are currently accepting enrollees for this trial, distributed among cities such as Memphis, Petersburg and Prairie Village. It is recommended to select the closest location in order to minimize travel costs when participating."

Answered by AI

Who else is applying?

What state do they live in?
Wisconsin
Florida
Texas
Other
How old are they?
< 18
18 - 65
What site did they apply to?
Cutting Edge Research Group, Inc
Clinical Neuroscience Solutions, Inc.
Family Psychiatry of The Woodlands
Other
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How many prior treatments have patients received?
3+
1

Why did patients apply to this trial?

My medical insurance has put me in a bad position regarding my ADHD treatment & I don't know where else to look.
PatientReceived 2+ prior treatments
I've read a lot of RCT on ADHD and I think Guanfacine is a promising drug (in comparison with methylphenidate products and all the amphetamine types).
PatientReceived 1 prior treatment
I've read a lot of RCT on ADHD and I think Atomoxetine is a promising drug (in comparison with methylphenidate products and all the amphetamine types).
PatientReceived 2+ prior treatments

How responsive is this trial?

Most responsive sites:
  1. Center for Psychiatry and Behavioral Medicine, Inc.: < 24 hours
Typically responds via
Email
Average response time
  • < 1 Day
~82 spots leftby Dec 2025